Imlunestrant monotherapy significantly improved PFS compared with standard endocrine therapy, with a median PFS of 5.5 months vs 3.8 months. The combination of imlunestrant and abemaciclib further ...

Eli Lilly (LLY) announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen receptor degrader, or SERD, in patients with estrogen receptor ...

Eli Lilly (LLY) and Company announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen receptor degrader, or SERD, in patients with estrogen ...

(RTTNews) - Eli Lilly and Company (LLY) Wednesday reported results from the Phase 3 EMBER-3 study of its drug candidate imlunestrant, in patients with advanced breast cancer. In the EMBER-3 study ...

“The median progression free survival observed in EMBER-3 is among the most compelling we've seen in [the trial population] ...

The result came from the phase 3 EMBER-3 trial. In patients without ESR1 mutations, imlunestrant and the control group showed no difference in PFS. This group’s result reduced the Lilly med’s ...

Burstein added that results from EMBER-3, as well as other data, suggest that combining these oral SERDs with a second-line CDK4/6 inhibitor such as abemaciclib "can achieve substantial durations ...

"The main purpose of this EMBER-3 trial was to evaluate the role of imlunestrant, a brain-penetrant oral SERD, as monotherapy or in combination with the CDK4/6 inhibitor, abemaciclib, in patients ...

“The main purpose of this EMBER-3 trial was to evaluate the role of imlunestrant, a brain-penetrant oral SERD, as monotherapy or in combination with the CDK4/6 inhibitor, abemaciclib, in ...

SAN ANTONIO — Second-line treatment with imlunestrant improved progression-free survival compared with standard endocrine monotherapy in patients with advanced estrogen receptor (ER)–positive ...

The main purpose of this EMBER-3 trial was to evaluate the role of imlunestrant, a brain-penetrant oral SERD, as monotherapy or in combination with the CDK4/6 inhibitor, abemaciclib, in patients ...

New York, NY 10065. A list of the members of the EMBER-3 Study Group is provided in the Supplementary Appendix, available at NEJM.org.